Industry

LEWISVILLE, Texas–(BUSINESS WIRE)–CareView Communications, Inc. (“CareView” or the “Company”) (OTCQB: CRVW), an information technology provider to the healthcare industry, today announced the signing of San Francisco VA Health Care System (“San Francisco VA”), San Francisco, CA, under its partnership with Decisive Point Consulting Group, LLC (DPCG). DPCG is a Service-Disabled Veteran-Owned Small Business specializing in … [Read more…]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences: Guggenheim 4th Annual Neuro/Immunology Conference on Tuesday, November 15, 2022, from 2:10-2:35 p.m. ET. Piper … [Read more…]

MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will present at the 34th Annual Piper Sandler Healthcare Conference. AtriCure’s management is scheduled to present on Wednesday, November 30, 2022, at 9:30 a.m. Eastern … [Read more…]

Co-led by Mubadala Capital and Horizons Ventures, funding will power Juvena’s artificial intelligence-enabled drug discovery platform to map the therapeutic potential of secreted proteins REDWOOD CITY, Calif.–(BUSINESS WIRE)–Juvena Therapeutics, Inc. (“Juvena”), a biotechnology company scaling a computational platform to map the therapeutic potential of secreted proteins, announced today that it has raised $41 million in … [Read more…]

MAHWAH, N.J.–(BUSINESS WIRE)–KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development of innovative and easy-to-use subcutaneous infusion solutions, today announced the progression of its agreement with Kira Pharmaceuticals, including expansion into three important additional indications. Kira will utilize KORU Medical’s Freedom System for Phase … [Read more…]

The Phase II multi-center, open label trial will evaluate BT8009 administered at the recommended Phase II doses of 5mg/m2 and 7.5mg/m2 Phase I dose escalation cohorts complete; results to be presented at a medical conference in 1H 2023 Confirmed RECIST response in a non-small cell lung cancer patient CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc … [Read more…]

– Allogeneic CAR T Program Updates Planned for Late Q4 2022 or Early Q1 2023 – Abstract Showcasing Functional Attributes of Azer-cel (PBCAR1091) Accepted for Presentation at the 64th American Society of Hematology (ASH) Annual Meeting – Preclinical Research on In Vivo Gene Editing Programs Presented at the European Society of Gene & Cell Therapy … [Read more…]

ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $21.3 million in the third quarter of 2022 (+23% vs. 2Q 2022) Cash runway expected into early 2025 Company to host conference call today at 8:30 a.m. EST LAUSANNE, Switzerland–(BUSINESS WIRE)–ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the third quarter ended September 30, 2022 and provided … [Read more…]

Study demonstrated minimal-to-no systemic exposure despite maximal use Subjects were as young as 2 years old with up to 90% body surface area (BSA) affected and a mean BSA of 43% Maximal usage study utilized same dose of VTAMA cream, 1% currently FDA-approved for adult plaque psoriasis LONG BEACH, Calif. & BASEL, Switzerland–(BUSINESS WIRE)–Dermavant Sciences, … [Read more…]

Preclinical data support the clinical potential of Turnstone’s next-generation Selected TIL therapy to improve TIL efficacy against solid tumor malignancies Presentations highlight novel method to select the most potent tumor-reactive T-cells (Selected TILs) with the potential to overcome the limitations of conventional TIL-based therapies SAN DIEGO–(BUSINESS WIRE)–#SITC2022–Turnstone Biologics Corp, a clinical-stage biotechnology company developing next-generation … [Read more…]